ES2555661T3 - Endorribonucleasas de ARNbc - Google Patents
Endorribonucleasas de ARNbc Download PDFInfo
- Publication number
- ES2555661T3 ES2555661T3 ES12735349.8T ES12735349T ES2555661T3 ES 2555661 T3 ES2555661 T3 ES 2555661T3 ES 12735349 T ES12735349 T ES 12735349T ES 2555661 T3 ES2555661 T3 ES 2555661T3
- Authority
- ES
- Spain
- Prior art keywords
- seq
- endoribonuclease
- sequence
- dsrna
- nucleotide sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 108010093099 Endoribonucleases Proteins 0.000 title abstract description 51
- 108091032973 (ribonucleotides)n+m Proteins 0.000 title abstract description 28
- 102000040650 (ribonucleotides)n+m Human genes 0.000 title abstract description 24
- 102000002494 Endoribonucleases Human genes 0.000 title description 2
- 102100030011 Endoribonuclease Human genes 0.000 abstract description 45
- 238000003776 cleavage reaction Methods 0.000 abstract description 37
- 239000000758 substrate Substances 0.000 abstract description 37
- 230000007017 scission Effects 0.000 abstract description 33
- 230000000694 effects Effects 0.000 abstract description 11
- 108091035707 Consensus sequence Proteins 0.000 abstract description 6
- 125000003275 alpha amino acid group Chemical group 0.000 abstract description 3
- 230000035772 mutation Effects 0.000 abstract description 2
- 239000002773 nucleotide Substances 0.000 description 64
- 238000006467 substitution reaction Methods 0.000 description 39
- 108020004999 messenger RNA Proteins 0.000 description 30
- 125000003729 nucleotide group Chemical group 0.000 description 30
- 108020004566 Transfer RNA Proteins 0.000 description 25
- 108091034117 Oligonucleotide Proteins 0.000 description 18
- 238000002360 preparation method Methods 0.000 description 17
- 108090000623 proteins and genes Proteins 0.000 description 15
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 14
- 238000006243 chemical reaction Methods 0.000 description 14
- 102000004169 proteins and genes Human genes 0.000 description 13
- 235000018102 proteins Nutrition 0.000 description 11
- 239000013612 plasmid Substances 0.000 description 10
- 108020004414 DNA Proteins 0.000 description 9
- 102000004190 Enzymes Human genes 0.000 description 9
- 108090000790 Enzymes Proteins 0.000 description 9
- 229940088598 enzyme Drugs 0.000 description 9
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 9
- 235000014469 Bacillus subtilis Nutrition 0.000 description 8
- 239000011780 sodium chloride Substances 0.000 description 7
- 241000193755 Bacillus cereus Species 0.000 description 6
- 244000063299 Bacillus subtilis Species 0.000 description 6
- 241000605986 Fusobacterium nucleatum Species 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- 230000003321 amplification Effects 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 6
- 229930027917 kanamycin Natural products 0.000 description 6
- 229960000318 kanamycin Drugs 0.000 description 6
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 6
- 229930182823 kanamycin A Natural products 0.000 description 6
- 238000003199 nucleic acid amplification method Methods 0.000 description 6
- 238000003786 synthesis reaction Methods 0.000 description 6
- HMFHBZSHGGEWLO-SOOFDHNKSA-N D-ribofuranose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-SOOFDHNKSA-N 0.000 description 5
- PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 description 5
- HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 description 5
- 239000000499 gel Substances 0.000 description 5
- 239000012139 lysis buffer Substances 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 239000013598 vector Substances 0.000 description 5
- NYHBQMYGNKIUIF-UUOKFMHZSA-N Guanosine Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O NYHBQMYGNKIUIF-UUOKFMHZSA-N 0.000 description 4
- 125000000539 amino acid group Chemical group 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- 230000000239 endoribonucleolytic effect Effects 0.000 description 4
- 239000012634 fragment Substances 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 150000002500 ions Chemical class 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 230000011987 methylation Effects 0.000 description 4
- 238000007069 methylation reaction Methods 0.000 description 4
- 108090000765 processed proteins & peptides Proteins 0.000 description 4
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 3
- 241000588724 Escherichia coli Species 0.000 description 3
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 3
- 239000011543 agarose gel Substances 0.000 description 3
- 235000004279 alanine Nutrition 0.000 description 3
- 125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 description 3
- 238000010276 construction Methods 0.000 description 3
- 230000002255 enzymatic effect Effects 0.000 description 3
- 229920002704 polyhistidine Polymers 0.000 description 3
- 229920001184 polypeptide Polymers 0.000 description 3
- 102000004196 processed proteins & peptides Human genes 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 239000011541 reaction mixture Substances 0.000 description 3
- 241001515965 unidentified phage Species 0.000 description 3
- 102000012410 DNA Ligases Human genes 0.000 description 2
- 108010061982 DNA Ligases Proteins 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 108090000190 Thrombin Proteins 0.000 description 2
- 238000010367 cloning Methods 0.000 description 2
- 230000002616 endonucleolytic effect Effects 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 238000002703 mutagenesis Methods 0.000 description 2
- 231100000350 mutagenesis Toxicity 0.000 description 2
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 2
- 229920002401 polyacrylamide Polymers 0.000 description 2
- 239000011535 reaction buffer Substances 0.000 description 2
- 238000012163 sequencing technique Methods 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 101100024289 Bacillus subtilis (strain 168) mrnC gene Proteins 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- MIKUYHXYGGJMLM-GIMIYPNGSA-N Crotonoside Natural products C1=NC2=C(N)NC(=O)N=C2N1[C@H]1O[C@@H](CO)[C@H](O)[C@@H]1O MIKUYHXYGGJMLM-GIMIYPNGSA-N 0.000 description 1
- NYHBQMYGNKIUIF-UHFFFAOYSA-N D-guanosine Natural products C1=2NC(N)=NC(=O)C=2N=CN1C1OC(CO)C(O)C1O NYHBQMYGNKIUIF-UHFFFAOYSA-N 0.000 description 1
- 238000001712 DNA sequencing Methods 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 102220466540 Gastrokine-1_S86A_mutation Human genes 0.000 description 1
- 239000006142 Luria-Bertani Agar Substances 0.000 description 1
- 102220492952 Nuclear RNA export factor 1_R82A_mutation Human genes 0.000 description 1
- 101710163270 Nuclease Proteins 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 108010002747 Pfu DNA polymerase Proteins 0.000 description 1
- 102220517289 Phosphate-regulating neutral endopeptidase PHEX_N83A_mutation Human genes 0.000 description 1
- 102220480790 Platelet glycoprotein VI_N92A_mutation Human genes 0.000 description 1
- 102220480792 Platelet glycoprotein VI_R80A_mutation Human genes 0.000 description 1
- 108010021757 Polynucleotide 5'-Hydroxyl-Kinase Proteins 0.000 description 1
- 102000008422 Polynucleotide 5'-hydroxyl-kinase Human genes 0.000 description 1
- 108091030071 RNAI Proteins 0.000 description 1
- 229920002684 Sepharose Polymers 0.000 description 1
- 102100029862 Sulfotransferase 1E1 Human genes 0.000 description 1
- 102220520515 Sulfotransferase 1E1_K85A_mutation Human genes 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 102220532506 Vitamin D3 receptor_K79A_mutation Human genes 0.000 description 1
- 102220532509 Vitamin D3 receptor_K91A_mutation Human genes 0.000 description 1
- 108010006886 Vitrogen Proteins 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 125000000637 arginyl group Chemical group N[C@@H](CCCNC(N)=N)C(=O)* 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 1
- 239000004327 boric acid Substances 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000009368 gene silencing by RNA Effects 0.000 description 1
- 229940029575 guanosine Drugs 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 1
- 230000009916 joint effect Effects 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 150000007523 nucleic acids Chemical group 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 102220225095 rs751226641 Human genes 0.000 description 1
- 102220094019 rs757569689 Human genes 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000013049 sediment Substances 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 229960004072 thrombin Drugs 0.000 description 1
- 238000000844 transformation Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/52—Genes encoding for enzymes or proenzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
- C12N9/22—Ribonucleases [RNase]; Deoxyribonucleases [DNase]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P19/00—Preparation of compounds containing saccharide radicals
- C12P19/26—Preparation of nitrogen-containing carbohydrates
- C12P19/28—N-glycosides
- C12P19/30—Nucleotides
- C12P19/34—Polynucleotides, e.g. nucleic acids, oligoribonucleotides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y301/00—Hydrolases acting on ester bonds (3.1)
- C12Y301/26—Endoribonucleases producing 5'-phosphomonoesters (3.1.26)
- C12Y301/26003—Ribonuclease III (3.1.26.3)
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Enzymes And Modification Thereof (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161494574P | 2011-06-08 | 2011-06-08 | |
| PL395178A PL222511B1 (pl) | 2011-06-08 | 2011-06-08 | Endorybonukleazy dsRNA |
| PL39517811 | 2011-06-08 | ||
| US201161494574P | 2011-06-08 | ||
| PCT/PL2012/050020 WO2012169917A1 (en) | 2011-06-08 | 2012-06-07 | Dsrna endoribonucleases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2555661T3 true ES2555661T3 (es) | 2016-01-07 |
Family
ID=47296271
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES12735349.8T Active ES2555661T3 (es) | 2011-06-08 | 2012-06-07 | Endorribonucleasas de ARNbc |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US9238805B2 (OSRAM) |
| EP (1) | EP2718431B1 (OSRAM) |
| JP (1) | JP6075892B2 (OSRAM) |
| KR (1) | KR20140045371A (OSRAM) |
| CN (1) | CN103764821B (OSRAM) |
| AU (1) | AU2012267271B2 (OSRAM) |
| CA (1) | CA2837143C (OSRAM) |
| DK (1) | DK2718431T3 (OSRAM) |
| ES (1) | ES2555661T3 (OSRAM) |
| PL (1) | PL222511B1 (OSRAM) |
| WO (1) | WO2012169917A1 (OSRAM) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10501791B2 (en) | 2011-10-14 | 2019-12-10 | President And Fellows Of Harvard College | Sequencing by structure assembly |
| ES2953308T3 (es) | 2011-12-22 | 2023-11-10 | Harvard College | Composiciones y métodos para la detección de analitos |
| WO2014163886A1 (en) | 2013-03-12 | 2014-10-09 | President And Fellows Of Harvard College | Method of generating a three-dimensional nucleic acid containing matrix |
| ES2991004T3 (es) | 2011-12-22 | 2024-12-02 | Harvard College | Métodos para la detección de analitos |
| US9914967B2 (en) | 2012-06-05 | 2018-03-13 | President And Fellows Of Harvard College | Spatial sequencing of nucleic acids using DNA origami probes |
| MY177814A (en) | 2013-06-04 | 2020-09-23 | Harvard College | Rna-guided transcriptional regulation |
| US10179932B2 (en) | 2014-07-11 | 2019-01-15 | President And Fellows Of Harvard College | Methods for high-throughput labelling and detection of biological features in situ using microscopy |
| CN104306989A (zh) * | 2014-09-27 | 2015-01-28 | 郭和友 | 一种利用切割酶治疗细菌方法 |
| GB2559526B (en) | 2015-11-03 | 2021-02-17 | Harvard College | Method and apparatus for volumetric imaging of a three-dimensional nucleic acid containing matrix |
| PL415883A1 (pl) * | 2016-01-22 | 2017-07-31 | Międzynarodowy Instytut Biologii Molekularnej I Komórkowej | RNazy MiniIII, sposoby zmiany specyficzności cięcia sekwencji RNA przez RNazy MiniIII oraz ich zastosowania |
| EP4613756A3 (en) | 2016-04-25 | 2025-11-12 | President And Fellows Of Harvard College | Hybridization chain reaction methods for in situ molecular detection |
| CN118853848A (zh) | 2016-08-31 | 2024-10-29 | 哈佛学院董事及会员团体 | 将生物分子的检测组合到使用荧光原位测序的单个试验的方法 |
| GB2570412A (en) | 2016-08-31 | 2019-07-24 | Harvard College | Methods of generating libraries of nucleic acid sequences for detection via fluorescent in situ sequencing |
| WO2018134386A1 (en) * | 2017-01-23 | 2018-07-26 | Novozymes A/S | Host cells and methods for producing double-stranded rna |
| SG11202101934SA (en) | 2018-07-30 | 2021-03-30 | Readcoor Llc | Methods and systems for sample processing or analysis |
| WO2020076976A1 (en) | 2018-10-10 | 2020-04-16 | Readcoor, Inc. | Three-dimensional spatial molecular indexing |
| US20220049303A1 (en) | 2020-08-17 | 2022-02-17 | Readcoor, Llc | Methods and systems for spatial mapping of genetic variants |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5459392A (en) | 1977-10-14 | 1979-05-12 | Rikagaku Kenkyusho | Novel nuclease and its preparation |
| US20060057590A1 (en) | 2004-09-14 | 2006-03-16 | Azeddine Si-Ammour | RNA probes |
-
2011
- 2011-06-08 PL PL395178A patent/PL222511B1/pl unknown
-
2012
- 2012-06-07 CA CA2837143A patent/CA2837143C/en not_active Expired - Fee Related
- 2012-06-07 CN CN201280027648.7A patent/CN103764821B/zh not_active Expired - Fee Related
- 2012-06-07 KR KR1020137032364A patent/KR20140045371A/ko not_active Ceased
- 2012-06-07 EP EP12735349.8A patent/EP2718431B1/en not_active Not-in-force
- 2012-06-07 WO PCT/PL2012/050020 patent/WO2012169917A1/en not_active Ceased
- 2012-06-07 ES ES12735349.8T patent/ES2555661T3/es active Active
- 2012-06-07 AU AU2012267271A patent/AU2012267271B2/en not_active Ceased
- 2012-06-07 JP JP2014514835A patent/JP6075892B2/ja not_active Expired - Fee Related
- 2012-06-07 DK DK12735349.8T patent/DK2718431T3/en active
-
2013
- 2013-11-25 US US14/088,934 patent/US9238805B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| AU2012267271A1 (en) | 2013-12-12 |
| EP2718431B1 (en) | 2015-10-28 |
| DK2718431T3 (en) | 2015-11-16 |
| CA2837143A1 (en) | 2012-12-13 |
| PL395178A1 (pl) | 2012-12-17 |
| EP2718431A1 (en) | 2014-04-16 |
| JP2014518641A (ja) | 2014-08-07 |
| WO2012169917A1 (en) | 2012-12-13 |
| PL222511B1 (pl) | 2016-08-31 |
| CN103764821B (zh) | 2016-04-27 |
| CN103764821A (zh) | 2014-04-30 |
| US9238805B2 (en) | 2016-01-19 |
| AU2012267271B2 (en) | 2015-06-04 |
| KR20140045371A (ko) | 2014-04-16 |
| US20140087427A1 (en) | 2014-03-27 |
| JP6075892B2 (ja) | 2017-02-08 |
| CA2837143C (en) | 2016-01-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2555661T3 (es) | Endorribonucleasas de ARNbc | |
| US10787653B2 (en) | Marine DNA polymerases | |
| CN105802935B (zh) | 一种酯酶phe14及其编码基因和应用 | |
| JP7361694B2 (ja) | Ｄｎａポリメラーゼ | |
| JP6387722B2 (ja) | 改変型の耐熱性ＲｅｃＡタンパク質、該タンパク質をコードする核酸分子、該タンパク質を用いた核酸の増幅方法、及び核酸増幅用キット | |
| EP2718430B1 (en) | Sequence-specific engineered ribonuclease h and the method for determining the sequence preference of dna-rna hybrid binding proteins | |
| US20230092081A1 (en) | Single-strand binding protein | |
| Owen et al. | The identification of a novel alternatively spliced form of the MBD4 DNA glycosylase | |
| Stanisławska-Sachadyn et al. | The construction of bifunctional fusion proteins consisting of MutS and GFP | |
| US8017356B2 (en) | Endoribonuclease | |
| Möncke-Buchner et al. | Overexpression and affinity chromatography purification of the Type III restriction endonuclease EcoP15I for use in transcriptome analysis | |
| Chi et al. | Antiviral Type III CRISPR signalling via conjugation of ATP and AdoMet | |
| RU2809366C1 (ru) | Способ получения большого фрагмента Bst-полимеразы (варианты) | |
| US7989184B2 (en) | Endoribonuclease | |
| JP7612678B2 (ja) | 海洋性ｄｎａポリメラーゼｉ | |
| Pisarchik | A novel approach for selecting potent peptide inhibitors of the SARS-CoV2-Mpro protease | |
| CN119144585A (zh) | 一种限制性内切酶PvuI的生产方法 | |
| JP2007530046A (ja) | 新規モジュラーＩＩ型制限エンドヌクレアーゼＣｓｐＣＩ、および新規特異性を有するエンドヌクレアーゼを製造するためのモジュラーエンドヌクレアーゼの用途 | |
| CN105200036A (zh) | 一种利用整合宿主因子来提高基于pcr的基因合成技术灵敏度的方法 |